Tesch, Roberta team published research in Journal of Medicinal Chemistry in 2021 | 5315-25-3

5315-25-3, 2-Bromo-6-methylpyridine (2BMPy) is a bromopyridine derivative. It is formed when 2-chloro-6-methylpyridine is heated with bromotrimethylsilane. Its synthesis from various methods have been reported.
2-Bromo-6-methylpyridine is a building block in the preparation of nitrogen containing heterocyclic compounds.
2-Bromo-6-methylpyridine is an organic compound that belongs to the group of pyridinium halides. It is soluble in common solvents such as water, ethanol, and acetone. 2BMPy has been shown to act as a glutamate receptor antagonist and has been used in the study of glutamate receptors, including their subtypes. This chemical has also been shown to have antioxidant properties and can be used in the prevention of atherosclerosis., Computed Properties of 5315-25-3

Pyridine is colorless, but older or impure samples can appear yellow. 5315-25-3, formula is C6H6BrN, Name is 2-Bromo-6-methylpyridine. The pyridine ring occurs in many important compounds, including agrochemicals, pharmaceuticals, and vitamins. Historically, pyridine was produced from coal tar. Computed Properties of 5315-25-3.

Tesch, Roberta;Rak, Marcel;Raab, Monika;Berger, Lena M.;Kronenberger, Thales;Joerger, Andreas C.;Berger, Benedict-Tilman;Abdi, Ismahan;Hanke, Thomas;Poso, Antti;Strebhardt, Klaus;Sanhaji, Mourad;Knapp, Stefan research published 《 Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors》, the research content is summarized as follows. Salt-inducible kinases (SIKs) are key metabolic regulators. The imbalance in SIK function is associated with the development of diverse cancers, including breast, gastric, and ovarian cancers. Chem. tools to clarify the roles of SIK in different diseases are, however, sparse and are generally characterized by poor kinome-wide selectivity. Here, we have adapted the pyrido[2,3-d]pyrimidin-7-one-based p21-activated kinase (PAK) inhibitor G-5555 for the targeting of SIK, by exploiting differences in the back-pocket region of these kinases. Optimization was supported by high-resolution crystal structures of G-5555 bound to the known off-targets, MST3 and MST4, leading to a chem. probe, MRIA9, with dual SIK/PAK activity and excellent selectivity over other kinases. Furthermore, we show that MRIA9 sensitizes ovarian cancer cells to treatment with the mitotic agent paclitaxel, confirming earlier data from genetic knockdown studies and suggesting a combination therapy with SIK inhibitors and paclitaxel for the treatment of paclitaxel-resistant ovarian cancer.

5315-25-3, 2-Bromo-6-methylpyridine (2BMPy) is a bromopyridine derivative. It is formed when 2-chloro-6-methylpyridine is heated with bromotrimethylsilane. Its synthesis from various methods have been reported.
2-Bromo-6-methylpyridine is a building block in the preparation of nitrogen containing heterocyclic compounds.
2-Bromo-6-methylpyridine is an organic compound that belongs to the group of pyridinium halides. It is soluble in common solvents such as water, ethanol, and acetone. 2BMPy has been shown to act as a glutamate receptor antagonist and has been used in the study of glutamate receptors, including their subtypes. This chemical has also been shown to have antioxidant properties and can be used in the prevention of atherosclerosis., Computed Properties of 5315-25-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem